---
layout: default
title: Cetuximab
parent: 僅模型預測 (L5)
nav_order: 206
evidence_level: L5
indication_count: 10
---

# Cetuximab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Cetuximab: From Approved Oncology Indications to Non-seminomatous Lesion

## One-Sentence Summary

Cetuximab (DrugBank DB00002) is an anti-EGFR monoclonal antibody marketed in Malaysia under 2 registrations; the specific original approved-indication text is not captured in this data pull (data gap). The TxGNN model's top-ranked prediction for this drug is **Non-seminomatous Lesion**, but this specific signal is currently **unsupported by evidence** — **0 clinical trials** and **0 publications** were found for this drug–disease pair.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not captured in current data (original_indications field empty; MOA also a data gap — see below) |
| Predicted New Indication | Non-seminomatous Lesion |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L5 |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for Cetuximab in this evidence pack (flagged as a High-severity data gap, DG002). Based on information present elsewhere in this pack's literature evidence, Cetuximab is known to act as a chimeric IgG1 monoclonal antibody directed against the epidermal growth factor receptor (EGFR), and is used across several EGFR-driven epithelial cancers (e.g., colorectal cancer, head and neck squamous cell carcinoma, and salivary gland carcinoma appear repeatedly in the supporting literature retrieved for other candidate indications).

For the specific prediction featured here — **Non-seminomatous Lesion** — no clinical trial, ICTRP, or PubMed record was retrieved despite targeted searches. The rationale supplied with this candidate explicitly states that the link is "a TxGNN prediction score only, with no mechanistic literature support" for EGFR expression in non-seminomatous lesions. In other words, the association currently rests entirely on the graph-embedding model's output rank, not on any independent biological or clinical signal.

**Note:** This same evidence pack contains other TxGNN candidates for Cetuximab with meaningfully stronger support than this one — notably **cystic neoplasm** (rank 8, evidence level L2, driven by a Phase II trial in salivary/adenoid cystic carcinoma) and **pre-malignant neoplasm** (rank 10, evidence level L1, driven by a completed Phase II trial of cetuximab in high-risk pre-malignant upper aerodigestive lesions, NCT00524017). Reviewers evaluating this drug's repurposing potential should consider those candidates separately, as they are far better evidenced than the top-ranked prediction discussed in this report.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Malaysia Market Information

License records exist for Cetuximab (2 registrations, market status "已上市"/Marketed), but product name, dosage form, manufacturer, and approved-indication text were not populated in this data pull — a detailed product table cannot be presented without fabricating values.

---

## Cytotoxicity

Cetuximab is an antineoplastic biologic (anti-EGFR monoclonal antibody used across multiple epithelial cancers per the literature retrieved elsewhere in this pack), so this section applies.

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy (Anti-EGFR monoclonal antibody) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The featured prediction (Cetuximab → Non-seminomatous Lesion) has no clinical trial or literature evidence and rests solely on a TxGNN model score (Evidence Level L5); it does not meet the threshold to proceed past S0.

**To proceed, the following is needed:**
- TFDA/NPRA product label (warnings and contraindications) — currently a Blocking data gap (DG001), required before any S1 safety screening
- Cetuximab mechanism-of-action documentation from DrugBank — currently a High-severity data gap (DG002), required for mechanistic-link analysis
- Malaysia license/product detail (product name, dosage form, manufacturer, approved indication text) for the 2 existing registrations
- If this candidate is to be pursued further, independent literature or preclinical evidence connecting EGFR biology to non-seminomatous lesions
- Separately, consider prioritizing evaluation of the better-evidenced candidates already surfaced in this pack — **cystic neoplasm (L2)** and **pre-malignant neoplasm (L1)** — which have actual clinical trial support
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

